Original Research and the Latest News

How Next-Generation Probability of Success Forecasting Can Improve Clinical Trial Accuracy by 44%

by | January 16, 2026 | New Technology, Probability of Success | 0 Comments

Unlocking Next-Gen POS Forecasting for Biopharma Success In the high-stakes world of biopharma, advanced Probability of Success (POS) forecasting can revolutionize the landscape of clinical trials. By adopting next-gen POS forecasting models, companies can...

Not Your Grandparents’ Probability of Success Forecasts

by | November 9, 2025 | New Technology, Probability of Success | 0 Comments

Redefining Probability of Success in Pharma: A Data-Driven Revolution In the world of pharmaceutical strategic planning and analytics, traditional Probability of Success (POS) forecasts are a familiar, yet often frustrating approach to assessing clinical risk. While...

Who’s Winning the Pharmaceutical R&D Pipeline Race in 2025

by | October 26, 2025 | Business, Data Analytics, Industry Trends, Market Scan, New Technology, Probability of Success | 0 Comments

The leaders, the contenders, and the strategies for success As we approach the 4th quarter of 2025, let’s review where the pharmaceutical industry’s leading companies rank in terms of overall pipeline strength.Roche, AstraZeneca, and Bristol-Myers Squibb sit in a...

Clinical Trial Success Rates: What Makes Some Companies Stand Out?

by | October 9, 2025 | New Technology, Probability of Success | 0 Comments

Our comprehensive analysis of over 30,000 clinical trials across more than 4,000 biopharmaceutical companies reveals significant variations in clinical trial success rates. This disparity exists even among trials in the same phase and targeting the same disease,...

Recent Posts

Recent Tweets

Ozmosi Follow

BioPharma/Biotech Intel. Daily $XBI $XPH Market Movers Database: https://t.co/IBOqbSoYuc Clinical trial tools: https://t.co/A77u9Q84Dc https://t.co/AQERg9nHrb

OzmosiHealth
ozmosihealth Ozmosi @ozmosihealth ·
11 Oct

$MIRM +5.59% today

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

More Info: https://pryzm.ozmosi.com/product/5770

Reply on Twitter 2109389340841578517 Retweet on Twitter 2109389340841578517 Like on Twitter 2109389340841578517 Twitter 2109389340841578517
ozmosihealth Ozmosi @ozmosihealth ·
11 Oct

$TRAX -0.66% today

First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026

More Info: https://pryzm.ozmosi.com/product/27747

Reply on Twitter 2109389338052325385 Retweet on Twitter 2109389338052325385 Like on Twitter 2109389338052325385 Twitter 2109389338052325385
ozmosihealth Ozmosi @ozmosihealth ·
11 Oct

$BBIO

Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1

More Info: https://pryzm.ozmosi.com/product/741

Reply on Twitter 2109328944793337956 Retweet on Twitter 2109328944793337956 Like on Twitter 2109328944793337956 Twitter 2109328944793337956
ozmosihealth Ozmosi @ozmosihealth ·
10 Oct

$LBRX

LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress

More Info: https://pryzm.ozmosi.com/product/37776

Reply on Twitter 2108921255219122237 Retweet on Twitter 2108921255219122237 Like on Twitter 2108921255219122237 Twitter 2108921255219122237
Load More

Get Started with OZMOSI

We synthesize and process insights, delivering what you need quickly, effectively, and efficiently.

Get in Touch

info@ozmosi.com
(732) 701-7807

600 Warren Ave,
Spring Lake, NJ 07762